France Radiation Oncology Market

France Radiation Oncology Market Insights Forecasts to 2035

• The France Radiation Oncology Market Size Was Estimated at USD 349.98 Million in 2024
• The France Radiation Oncology Market Size is Expected to Grow at a CAGR of Around 10.11% from 2025 to 2035
• The France Radiation Oncology Market Size is Expected to Reach USD 1,009.98 Million by 2035

 

According to a research report published by Decision Advisor & Consulting, The France Radiation Oncology Market Size is Anticipated to reach USD 1,009.98 Million by 2035, Growing at a CAGR of 10.11% from 2025 to 2035. The France radiation oncology market is driven by the rising incidence of cancer, an aging population, advancements in radiotherapy technologies, strong government support through national cancer plans, increasing healthcare expenditure, and growing adoption of precise, patient-centric radiation treatments.

 

Market Overview

The France radiation oncology market refers to the technologies, equipment, software, and clinical services utilized for the diagnosis, planning, and treatment of cancer through therapeutic radiation across the country. The market comprises various radiation therapies such as external beam radiation therapy systems, brachytherapy, stereotactic and image-guided techniques, proton therapy, and the corresponding treatment, planning, and imaging solutions. The market in France operates within the framework of a well-established, publicly funded healthcare system and is influenced by several factors, such as strict regulatory standards, national cancer control programs, the rise in cancer cases, technological advancements, and an increasing emphasis on precise, patient-centric cancer treatment.

 

France's embrace of the radiation oncology sector is primarily driven by a high and increasing cancer burden that quite clearly shows the need for such a service in managing the health of the population. The country sees over 430,000 new cancer cases annually, and radiotherapy accounts for the treatment of about 60–70% of cancer patients, which is roughly 190,000 patients yearly. As the France population gets older and the incidence of breast, prostate, lung, and colorectal cancers continues to increase, the country is performing millions of radiation therapy sessions each year, thus making radiation oncology one of the vital and largely utilized components of cancer treatment in its publicly funded healthcare system.

 

The France radiation oncology market is strengthened by government support, the clearly identified future needs, and the innovation-driven opportunities. In the framework of the National Cancer Strategy 2021-2030, the France government has allocated around €1.7 billion to improving cancer prevention, treatment quality, and infrastructure, with radiotherapy being one of the priority areas. Moreover, the France 2030 investment plan provides additional support for the health and technological innovation sectors with a budget of €54 billion, of which €37 million is earmarked for the development of advanced radiotherapy techniques. Combined with the continued public funding, the grants for research, and the modernization of the cancer centers, these measures are a strong signal to the advanced radiation oncology technology industry for the increased uptake of their products. From a marketing viewpoint, therefore, France is a high-value, stable, and friendly innovation market.

 

Report Coverage

This research report categorizes the market for the France radiation oncology market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France radiation oncology market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France radiation oncology market.

 

Driving Factors

The France radiation oncology market is largely influenced by France's massive cancer burden, with the incidence of new cancers exceeding 430,000 cases each year. The aging population and the fact that 60-70% of cancer treatments are radiotherapy-based also contribute to the growth. Furthermore, development of precision radiotherapy technologies, hefty public support via the €1.7 billion National Cancer Strategy and the €54 billion France 2030 plan, comprehensive reimbursement coverage, and perpetual upgrading of cancer care facilities and research are other factors that promote market growth.

 

Restraining Factors

The France radiation oncology market is restrained by the high cost of advanced radiotherapy equipment, strict regulatory and approval processes, budget limitations in public hospitals, and a shortage of skilled professionals, as well as uneven regional access to modern radiotherapy facilities.

 

Market Segmentation

The France radiation oncology market share is classified into type and application.

• The external beam radiation therapy segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The France radiation oncology market is segmented by type into external beam radiation therapy and internal beam radiation therapy. Among these, the external beam radiation therapy segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The external beam radiation therapy segment is growing because of its wide clinical applicability, advanced technologies like IMRT and IGRT, high availability across French cancer centers, favorable reimbursement, and rising cancer incidence, making it the most commonly used radiotherapy approach.

 

• The breast cancer segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.

The France radiation oncology market is segmented by application into blood cancer, breast cancer, gastrointestinal cancer, lung cancer, skin cancer, and others. Among these, the breast cancer segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. The breast cancer segmental growth is due to its high prevalence in France, widespread use of radiotherapy after surgery, strong screening programs enabling early diagnosis, advanced targeted radiotherapy techniques, and favorable reimbursement support.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France radiation oncology market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Accuray
• C. R. Bard
• Elekta
• IBA Worldwide
• Varian Medical Systems
• Carl Zeiss Meditec
• iCAD
• IsoRay
• Mevion Medical Systems
• Nordion
• NTP Radioisotopes
• Canon Medical Systems
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Developments:

• In May 2025, Leo Cancer Care France and Centre Léon Bérard secured a Fonds Européen de Développement Régional (FEDER) grant to advance upright proton radiation therapy with their Marie system, aiming to improve treatment efficiency, patient comfort, and accessibility within France’s radiation oncology landscape.

 

Market Segment

This study forecasts revenue at the France, regional, and country levels from 2020 to 2035. Decision Advisor has segmented the France radiation oncology market based on the below-mentioned segments:

 

France Radiation Oncology Market, By Type

• External Beam Radiation Therapy
• Internal Beam Radiation Therapy

 

France Radiation Oncology Market, By Application

• Blood Cancer
• Breast Cancer
• Gastrointestinal Cancer
• Lung Cancer
• Skin Cancer
• Others

 

FAQ’s

1. What is the France radiation oncology market size in 2024?

The France radiation oncology market size was estimated at USD 349.98 million in 2024.

 

2. What is the projected market size of the France radiation oncology market by 2035?

The France radiation oncology market size is expected to reach USD 1,009.98 million by 2035.

 

3. What is the CAGR of the France radiation oncology market?

The France radiation oncology market size is expected to grow at a CAGR of around 10.11% from 2024 to 2035.

 

4. What are the key growth drivers of the France radiation oncology market?

The France radiation oncology market is driven by the rising incidence of cancer, an aging population, advancements in radiotherapy technologies, strong government support through national cancer plans, increasing healthcare expenditure, and growing adoption of precise, patient-centric radiation treatments.

 

5. Which application segment dominated the market in 2024?

The breast cancer segment dominated the market in 2024.

 

6. What segments are covered in the France radiation oncology market report?

The France radiation oncology market is segmented on the basis of type and application.

 

7. Who are the key players in the France radiation oncology market?

Key companies include Accuray, C. R. Bard, Elekta, IBA Worldwide, Varian Medical Systems, Carl Zeiss Meditec, iCAD, IsoRay, Mevion Medical Systems, Nordion, NTP Radioisotopes, Canon Medical Systems, and others.

 

8. Who are the target audiences for this market report?

The report targets market players, investors, end-users, government authorities, consulting and research firms, venture capitalists, and value-added resellers (VARs).